Longeveron Inc. - Class A Common stock (LGVN)
0.7903
+0.0303 (3.99%)
NASDAQ · Last Trade: Aug 18th, 1:44 PM EDT
Detailed Quote
| Previous Close | 0.7600 |
|---|---|
| Open | 0.7500 |
| Bid | 0.7903 |
| Ask | 0.7983 |
| Day's Range | 0.7250 - 0.8000 |
| 52 Week Range | 0.6330 - 2.860 |
| Volume | 736,611 |
| Market Cap | 3.57M |
| PE Ratio (TTM) | -0.8590 |
| EPS (TTM) | -0.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,840,377 |
Chart
About Longeveron Inc. - Class A Common stock (LGVN)
Longeveron Inc is a biotechnology company focused on developing cellular therapies to address age-related and life-threatening conditions. The company specializes in the research and commercialization of innovative treatments, particularly those utilizing mesenchymal stem cells derived from umbilical cord tissue. Longeveron aims to improve the quality of life for patients suffering from diseases such as Alzheimer’s and cardiac dysfunction by harnessing the potential of these advanced therapies to promote regeneration and improve overall health outcomes. Through its commitment to scientific research and clinical trials, Longeveron is at the forefront of modern medicine, exploring new avenues for healing and enhancing longevity. Read More
News & Press Releases
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · August 14, 2025
Longeveron Inc. (LGVN) reported Q2 2025 earnings with revenue missing estimates at $320K but a narrower EPS loss of $0.33. Stock fell 3.5% post-earnings amid clinical progress in HLHS and Alzheimer's trials.
Via Chartmill · August 13, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · August 8, 2025
Via Benzinga · November 4, 2024
Via Benzinga · August 5, 2025
Via Benzinga · August 4, 2025
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via Chartmill · August 4, 2025
MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.
By Longeveron · Via GlobeNewswire · May 12, 2025
MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2025 and provided a business update.
By Longeveron · Via GlobeNewswire · May 8, 2025
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · February 28, 2025
Via Benzinga · October 28, 2024
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present ‘Important’ Lomecel-B(TM) Data at the 17th Clinical Trials on Alzheimer’s Disease Conference
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it will present a late breaking poster at the 17th edition of the Clinical Trials on Alzheimer’s Disease Conference (“CTAD24”). The poster is titled “Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer’s disease.” The conference is taking place in Madrid, Spain, from October 29, 2024, to November 1, 2024.
Via Investor Brand Network · October 14, 2024
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
Longeveron (NASDAQ: LGVN), a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be presenting at the 51st meeting of the Congenital Heart Surgeons’ Society. The meeting is scheduled for Oct. 27–28, 2024, in Chicago. Longeveron’s presentation will be part of the event’s Scientific Session II. Titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy,” the presentation is slated to begin at 3:10 p.m. ET on Oct. 27.
Via Investor Brand Network · October 9, 2024
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) CEO to Participate in Fireside Cat at UBS Virtual Organ Restoration and Cell Therapy Day
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at the upcoming UBS Virtual Organ Restoration and Cell Therapy Day. According to the announcement, Longeveron CEO Wa’el Hashad will be participating in a fireside chat during the Oct. 15, 2024, virtual event. During the fireside chat, Hashad will be talking with Ash Verma, SMID-cap biotech and specialty pharma analyst for UBS Equity Research Ash Verma. The event is slated to begin at 3 p.m. ET.
Via Investor Brand Network · October 7, 2024
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the Mesa
Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions. The company today announced that it will attend the Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine . The conference is scheduled for October 7-9, 2024, in Phoenix, Arizona.
Via Investor Brand Network · September 26, 2024
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Alignment with FDA on Development Pathway for Lomecel-B(TM) in HLHS
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). The meeting supported the advancement of Lomecel-B(TM) , a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (“ELPIS II”) for hypoplastic left heart syndrome (“HLHS”) . According to the announcement, Longeveron and the FDA reached foundational alignment on ELPIS II primary and secondary endpoints as well as on the need to submit the company’s prespecified Statistical Analysis Plan (“SAP”) and Chemistry, Manufacturing and Controls (“CMC”) readiness plan, including Lomecel-B(TM) stability and comparability data, for prior review.
Via Investor Brand Network · September 3, 2024
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, will be spotlighted at next month’s H.C. Wainwright 26th Annual Global Investment Conference; the event is scheduled for Sept. 9–11, 2024. According to the announcement, company officials are slated to present on Sept. 10 at 5 p.m. ET. Following the conference, an archived replay of the webcast will be available on the Longeveron website.
Via Investor Brand Network · August 27, 2024